Loading stock data…
SCYNEXIS, Inc. (SCYX)
$5.15-0.15 (-2.83%)
Market ClosedLast close Sep 8
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SCYNEXIS, Inc. in the Healthcare sector is trading at $5.15 with a market capitalization of $52M. Wall Street consensus targets $36.55 (3 analysts), implying a +609.6% move over the next 12 months. The stock is currently 51% below its 52-week high of $10.48, remaining 9.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +609.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $235,000 | $0↓ | $18.65M↑ | $334,000↓ | $1.36M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.78M↑ | -$16.94M↓ | $10.52M↑ | -$8.40M↑ | -$9.56M |
| Net Income | $7.40M↑ | -$21.30M↓ | $12.26M↑ | -$8.59M↓ | -$6.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$52.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.35%
Volume
Today's trading volume
33,068
Recent News
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
These are the upcoming stock splits for the week of June 1 to June 5, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate move that increases the number of shares outstanding while reducing the price of each share proportionally. Nothing changes about the company’s overall value, but the lower share price can make the stock appear more accessible to everyday investors and, in some cases, help boost trading activity. Not all stock splits work that way, however. Many companies t
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease
SCYNEXIS (SCYX) said Tuesday that it has entered into a securities purchase agreement with investors
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On February 26, 2026, SCYNEXIS, Inc. (NASDAQ:SCYX) announced that the first participants had been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of its second-generation triterpenoid antifungal therapy, SCY-247. The therapy […]
Scynexis: Q4 Earnings Snapshot
The Jersey City, New Jersey-based company said it had profit of 25 cents per share. The pharmaceutical company posted revenue of $18.6 million in the period. For the year, the company reported a loss of $8.6 million, or 17 cents per share.
Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...